Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Multi-centre, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Investigate Efficacy and Safety of ONO-2506PO Compared to Placebo, in the Presence of Riluzole, to Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS), Who Have Had Onset of Muscle Weakness Within 14 Months of Randomization
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Wien, Austria, 1100
- L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien
-
-
-
-
-
Brussels, Belgium
- UCL Saint-Luc
-
Leuven, Belgium, 3000
- UZ Leuven
-
-
-
-
-
Lille Cedex, France, 59037
- Hopital Roger Salengro - Clinique Neurologique, Neurologie A
-
Limoges Cedex, France, 87042
- Hopital Duruytren
-
Marseille, France, 13005
- Hôpital de la Timone
-
Montpellier cedex 5, France, 34295
- Hôpital de Chauliac
-
Nice cedex 3, France, 06202
- Hopital l-Archet 1
-
Paris, France, 75013
- Hopital LaPitie Salpetriere
-
-
-
-
-
Berlin, Germany, 13353
- Charite Campus Virchow, ALS Ambulanz
-
Bochum, Germany, 44789
- Neurologische Universitätsklinik Bergmannsheil
-
Erlangen, Germany, 91054
- Poliklinik der Universitat Erlangen-Nurnberg, Neurologische Klinik
-
Halle, Germany, 06120
- Martin-Luther-Universitat Halle-Wittenberg, Klinikum der Medizinischen Fakultat, Universitatsklinik und Poliklinik fur Neurologie
-
Hannover, Germany, 30623
- Medizinische Hochschule Hannover, Neurologische Klinik
-
Munchen, Germany
- Interdisziplinares Zentrum fur Palliativmedizin
-
Ulm, Germany, 89081
- Klinik und Poliklinik fur Neurologie der Universitat Ulm-Universitatsklinikum Ulm
-
Wiesbaden, Germany, 65191
- Deutsche Klinik fur Diagnostik, Fachbereich Neurologie
-
-
-
-
-
Milano, Italy, 20149
- Dipartimento di Neurologia e Laboratorio di Neuroscienze - Universita di Milano - IRCCS - Istituto Auxologico Italiano
-
Pavia, Italy, 27100
- Divisione di Neuroriabilitazione II - Fondazione Salvatore Maugeri - IRCCS
-
Torino, Italy, 10126
- Dipartimento di Neuroscienze - Divisione di Neurologia II - Azienda Ospedaliera S. Giovanni Battista - Molinette
-
-
-
-
-
Amsterdam, Netherlands
- Academic Medical Centre (AMC) Amsterdam - Dept of Neurology
-
Utrecht, Netherlands
- University Medial Center Utrecht
-
-
-
-
-
St. Gallen, Switzerland, 9007
- Kantonsspital St. Gallen, Muskelzentrum/ALS Clinic
-
-
-
-
-
London, United Kingdom
- Academic Neuroscience Centre
-
Preston, United Kingdom, PR29HT
- Royal Preston Hospital
-
Sheffield, United Kingdom
- University of Sheffield - Academic Neurology Unit
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of clinically possible, clinically probable laboratory-supported, clinically probable or clinically definite ALS (according to WNF EL Escorial diagnostic criteria, revised according to the Airlie House Conference 1998)
- Onset of muscle weakness within 14 months randomization
- Concomitant standard Riluzole therapy (50mg twice daily)
Exclusion Criteria:
- Presence of a tracheotomy, mechanical ventilation or non-invasive ventilation
- Requirement for prescription drugs used for potential neuroprotective benefit -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: E
ONO-2506PO in the presence of Riluzole
|
1200 mg QD / 18 months
0 mg QD / 18 months
|
|
Placebo Comparator: P
Placebo in the presence of Riluzole
|
1200 mg QD / 18 months
0 mg QD / 18 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of decline of respiratory function determined as SVC over the 12 month treatment period
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Survival
Time Frame: 12, 18 months
|
12, 18 months
|
|
Functional Assessment (ALSFRS-R)
Time Frame: 12, 18 months
|
12, 18 months
|
|
Muscle Strength (MRC muscle score)
Time Frame: 12, 18 months
|
12, 18 months
|
|
Quality of Life
Time Frame: 12, 18 months
|
12, 18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Tomohiro Kuwayama, Ono Pharmaceutical Co. Ltd
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ONO-2506POE014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.